Drew Moss

Heme/Onc Fellow NYULI. Researcher @MSKCancerCenter. MSMW/WMED/UofM alumnus. Oncology, clinical research, Tim Robinson fan. #GoBlue〽️ #OpinionsMyOwn

[Anirban Maitra @Aiims1742]

From @RevMedicines data on Zoldonrasib plus Daraxonrasib in 2nd & 3rd line metastatic #PancreaticCancer - presented at #ESMOGI26
Small numbers but even a few years back, who would have imagined survival curves like this in 2nd & 3rd line metastatic PANCREATIC cancer? Amazing!

[Drew Moss @DrewMoss]

@ibsraw The Big House would be way more electric fyg

[Drew Moss @DrewMoss]

@FionnualaCrowle @EileenMOReilly @TischCancer Congratulations 👏🏻👏🏻👏🏻

[Wungki Park, MD MS @CentralParkWMD]

POV: Your Apple Watch thinks something is wrong…

…but you’re just about to present at #ESMOGI26. 😄⌚️💕💗💜

Discussing the Phase II GLEAM study and joining conversations on the future of pancreatic cancer.

Worth every heartbeat. 💗

#PancreaticCancer #GIOncology #KRAS #ClinicalTrials @myESMO @CpcrMsk @MSKCancerCenter @MSK_DeptOfMed @oncodaily @OncoDailyGI

[Drew Moss @DrewMoss]

The calm before the storm!

[Wungki Park, MD MS @CentralParkWMD]

Ready.

One of my favorite moments before an oral presentation at a big stage is walking into an empty auditorium and breathing the air of this room.

Soon it will be filled with colleagues from around the world, all united by one goal - improving outcomes for patients with GI cancers.

Honored to share our work #CLDN18 #GLEAM at #ESMOGI26. Looking forward to the discussions ahead.

#Science We advance because we learn from negative result. #GRIT

#proffered #abstract
#GIOncology #PancreaticCancer #KRAS #TranslationalResearch @CpcrMsk @MSK_DeptOfMed @MSKCancerCenter @PanCAN @letswinpc @Pankind_Aus

[Wungki Park, MD MS @CentralParkWMD]

Ready.

One of my favorite moments before an oral presentation at a big stage is walking into an empty auditorium and breathing the air of this room.

Soon it will be filled with colleagues from around the world, all united by one goal - improving outcomes for patients with GI cancers.

Honored to share our work #CLDN18 #GLEAM at #ESMOGI26. Looking forward to the discussions ahead.

#Science We advance because we learn from negative result. #GRIT

#proffered #abstract
#GIOncology #PancreaticCancer #KRAS #TranslationalResearch @CpcrMsk @MSK_DeptOfMed @MSKCancerCenter @PanCAN @letswinpc @Pankind_Aus

[Drew Moss @DrewMoss]

Very very well deserved @EileenMOReilly ! A compassionate physician, researcher, and mentor!

[Memorial Sloan Kettering Cancer Center @MSKCancerCenter]

Congratulations to MSK gastrointestinal medical oncologist @EileenMOReilly on being honored with the Hope Through Compassion Award from the @lustgartenfdn. The award recognizes her dedication to patients and her leadership in developing innovative clinical research for #pancreaticcancer.

Watch to learn more about her approach to advancing pancreatic cancer research: https://t.co/ojuy5H8eyy

[Memorial Sloan Kettering Cancer Center @MSKCancerCenter]

Congratulations to MSK gastrointestinal medical oncologist @EileenMOReilly on being honored with the Hope Through Compassion Award from the @lustgartenfdn. The award recognizes her dedication to patients and her leadership in developing innovative clinical research for #pancreaticcancer.

Watch to learn more about her approach to advancing pancreatic cancer research: https://t.co/ojuy5H8eyy

[Nicholas Hornstein @GIMedOnc]

Had the chance to give the colorectal cancer update at Best of ASCO Los Angeles.

Always fun to summarize a year of CRC data in ~20 minutes while pretending that is a normal thing to ask of a human being.

4 takeaways (without getting into some of the really exciting drugs that are coming to CRC soon):

🔹 MSI-H CRC in complete clinical response on PD-1
Stopping at confirmed cCR looks safe. Maintenance may add toxicity without clear benefit.

🔹 BRAF V600E MSS mCRC
Encorafenib + cetuximab + chemotherapy is now a 1L standard. FOLFIRI is a great option, and FOLFOX is reasonable too. Either way, the targeted therapy backbone is here.

🔹 ctDNA / MRD
Not fully in NCCN yet, but increasingly actionable. I escalate select stage II patients, use it to frame de-escalation discussions, and strongly favor trials when possible.

🔹 Exercise
Prescribe it like we prescribe oxaliplatin.
30 min, 3x/week, ~80% max HR improves DFS/OS and is cost-saving.

CRC is moving fast. The challenge now is not just knowing the data, but figuring out how to apply it thoughtfully in clinic.

Grateful to be part of the conversation.

@TheGutOncLab @Onco_Nexus @OncoAlert @TotalHealthConf

[Wungki Park, MD MS @CentralParkWMD]

GRIT = GI Innovative RAS Therapeutics.

Exciting to see leaders (@EileenMOReilly @debschrag @DrVickersMSK Jeff Drebin @MHLars ) across pancreatic cancer and oncology come together as we enter a new chapter of RAS-directed therapies. 💜

Reminiscing our time in the last 4 years and all the thrills we had seeing their tumor marker and CT improving dramatically in our first patients.

From KRAS inhibition to immune modulation and more meaningful combinations, the future is being built through collaboration, innovation, and translation.

#KRAS #RAS #PancreaticCancer #GRIT #ASCO26 @ASCO
@MSK_DeptOfMed @MSKCancerCenter @NatPancFdn @PanCAN @letswinpc @Pankind_Aus @KRASKickers @OncBrothers

[NEJM @NEJM]

Presented at #ASCO26:

Among patients with previously treated metastatic pancreatic ductal adenocarcinoma, the RAS(ON) inhibitor daraxonrasib led to significantly longer overall survival and progression-free survival than chemotherapy. Full phase 3 RASolute 302 trial results: https://t.co/xwLWBZYRzq

@ASCO

[Nieves Martinez Lago MD PhD @DraMartinezLago]

🧬 #ASCO2026 | BREAKWATER Cohort 3

✔️ EC + FOLFIRI vs FOLFIRI ± bev
📈 ORR: 64.4% vs 39.2%

📈 mPFS: 15.2 vs 8.3 mo
• HR 0.44 (P=0.0002)

📈 OS benefit
• HR 0.56
• 18-mo OS: 72.0% vs 54.5%

⚠️ No new safety signals

🎯 EC + FOLFIRI emerges as a new 1L BRAF V600E mCRC
@OncoAlert

[Memorial Sloan Kettering Cancer Center @MSKCancerCenter]

MSK gastrointestinal medical oncologist @EileenMOReilly presented to a packed room at #ASCO26 today, discussing new findings and the growing momentum behind #RAS-targeted therapies in #pancreaticcancer.

[MSK Department of Medicine @MSK_DeptOfMed]

Join MSK gastrointestinal medical oncologist Dr. @EileenMOReilly at #ASCO26 for an education session on novel approaches and future directions in targeting KRAS-driven cancers, beyond the G12C mutation. @MSKCancerCenter

🕒 Saturday, May 30 | 1:49 p.m. CDT

Learn more: https://t.co/nEseaf8Xbp

[Wungki Park, MD MS @CentralParkWMD]

Pembrolizumab and Olaparib Maintenance in Pancreatic Cancer: Interpreting the POLAR Data @GiOncNow

#PrecisionImmunotherapy #POLAR @MSK_DeptOfMed @PICIatMSK @MSKCancerCenter @EileenMOReilly

https://t.co/pa9dkbBWOX

📽️ Summary:
https://t.co/WxT0XrT69i

[Anirban Maitra @Aiims1742]

The crowd surrounding this @EileenMOReilly late breaking poster is going to be huge!
Also today afternoon.
#AACR26

[Wungki Park, MD MS @CentralParkWMD]

Landscape of #PancreaticCancer treatment is changing!

@EileenMOReilly, a gastrointestinal medical oncologist @MSK_DeptOfMedwho was involved with the studies on daraxonrasib, says the encouraging findings about daraxonrasib "hopefully set the stage for building on targeted therapy as a major backbone for the treatment of pancreas cancer, and a key goal now is to build and extend these results in all stages."

“I’ve already told my colleagues that today is an inflection point that if things stays positive, everything should change,” says Dr. Wungki Park @CentralParkWMD, a pancreatic cancer specialist @MSKCancerCenter, who was involved in the early human trials of daraxonrasib. “There will be pre-daraxonrasib and post-daraxonrasib. This is a really, really good outcome.”

Congratulations to Elraglusib team! https://t.co/u6xyQItlXd Devalingam Mahalingam,@rachnatshroffBenedito Carneiro and@GIcancerDoc

https://t.co/gGwufRCvl7

[ESPN @espn]

GO. BLUE. 🏆

MICHIGAN IS THE FIRST BIG TEN TEAM TO WIN A NATIONAL CHAMPIONSHIP SINCE 2000! 🔥

[Memorial Sloan Kettering Cancer Center @MSKCancerCenter]

A new drug is showing promise in lung and pancreatic cancers (two of the most aggressive forms of cancer) by targeting one of the most common cancer-driving mutations.

Researchers at Memorial Sloan Kettering Cancer Center (MSK), including gastrointestinal medical oncologist @CentralParkWMD who led the global phase 1 clinical trial, shared results published in the @NEJM.

The trial tested setidegrasib, a drug that tags and destroys the cancer-causing protein produced by the KRAS G12D mutation. This new method for targeting a long-known mutation is called a KRAS degrader.

KRAS mutations are present in about 1 in 5 cancers. The G12D subtype drives about 40% of pancreatic cancers and 5% of non-small cell lung cancers.

“This drug’s potential is exciting,” says Dr. Park, “because the trial results suggest that setidegrasib can not only extend life for some patients with these aggressive cancers, it also has a very good safety profile, meaning the drug was well-tolerated with side effects that can be managed quite easily."

Learn more about this research: https://t.co/HCEVr2ltIj

[Catherine O’Connor @CatherineaOC]

It's hard to believe I started working on POLAR my first year of college, and now I am finishing my first clinical rotation on Friday. Endlessly grateful for everything I learned over the past 5 years from @CentralParkWMD, @EileenMOReilly & all the patients who were part of POLAR